2. During the mid-production period, the duck population in this period has already entered the peak output and has been producing eggs for more than 100 days. It consumes a lot of energy. During this period, the nutrition level should be appropriately increased on the basis of the previous period. The protein content should reach 20%. And pay attention to the increase of calcium, you can add 1% -2% of the granular shell powder in the powder, or put shell powder in the feed tank for free feeding, and feed the green feed or add more Vitamins. The lighting time is maintained at 16-17 hours. Attention should be paid to observing whether the eggshell quality changes significantly, whether the egg production time is concentrated, whether the mental state is good, whether the feathers are wet after bathing, etc., so that effective measures can be taken in time.
3. After the long-term continuous laying of laying ducks in the post-laying period, the laying rate will continue to decline. If managed properly during this period, the duck group's average egg production rate can still be maintained at 75%-80%. If the duck has a fattening trend at this time, the energy water in the diet should be appropriately lowered, or the amount of green feed should be increased or the feed intake must be controlled. If the duckling production rate remains at around 80% and the body weight has decreased, some animal protein content should be increased.
If the egg production rate has dropped to about 60%, it should be eliminated as soon as possible.
Our factory mainly produces various anticancer active pharmaceutical ingredients (API) and their intermediates, most of which meet the USP/EP/JP standard.At the same time, we maintain long-term and close cooperation with many research institutions and universities, Our co-production plants are located in Anhui, Jiangsu, Zhejiang and Inner Mongolia. Our major products are antineoplastic, cardiovascular and antibiotics and their intermediates.
Our major anticancer products are Sorofenib, Sunitinib, Axitinib, Ibrutinib, Enzalutamide, Vemurafenib, Lenvatinib, Decitabine, Venetoclax and their intermediates.
If you have any questions, please contact with us directly. Apis And Intermediates are supplied by Dingmin Pharmaceutical with high quality and best price. Welcome to visit or audit our factory at any time!
Cas 231277-92-2,Apis And Intermediates,Lapatinib Ditosylate Monohydratei
Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd , http://www.dingminpharma.com